NanoMab Enters into Agreement with University Hospital Aachen to initiate a Cancer Therapy Programme utilising next generation NM-02 radiopharmaceutical product.
Translational Programme established for FIH late stage HER2 positive breast cancer in Q4 2020.
London, May 20th, 2020: NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced a collaboration with University Hospital Aachen to initiate a cancer therapy programme to bring a novel radiopharmaceutical product to patients with HER2 positive breast cancer.
The programme will utilise Nanomab’s next generation NM-02 radiopharmaceutical product (a theranostic pairing of a diagnostic and a therapeutic medical radioisotope coupled to a camelid single domain antibody) targeting a First in Human (FIH) administration in Q4 2020.
Paul Edwards, Nanomab’s CEO commented, “We are delighted to announce this collaboration with the Department of Nuclear Medicine at University Hospital Aachen, which will allow us to assess the therapeutic benefits of Nanomab’s NM-02 product, following evaluations in preclinical models, on patients with advanced breast and other HER2 positive cancers such as gastric cancer. The aim is to show that our product has the ability to shrink metastatic cancers and improve the quality of life for patients.”
For more information:
Paul Edwards. Tel: +44 (0)7771 575374
Email: p.m.edwards@nano-mab.com
Media
Richard Hayhurst/Janet Joy RHApr
Tel: +44 (0)7711 821 527